IP Library Granted Patent US 12,649,020
Granted Patent B2
US 12,649,020 · App. 17/705,658 · Granted Jun 9, 2026

Therapy prediction and optimization for renal failure blood therapy

Inventors: Alp Akonur (Evanston, IL); John Kenneth Leypoldt (Libertyville, IL); Ying-Cheng Lo (Green Oaks, IL); Baris Ugur Agar (Chicago, IL)
Assignees: Vantive US Healthcare LLC; Vantive Health GMBH
A61M1/1603A61M1/16A61M1/1611A61M1/1613A61M1/1619A61M1/3609A61M2202/0498A61M2205/15A61M2205/3584A61M2205/50A61M2205/502A61M2205/52A61M2230/20G16H20/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,649,020
App. No.
17/705,658
Granted
Jun 9, 2026
Kind
B2
Abstract

A renal failure blood therapy system includes a memory device storing a therapy target for a patient. The system also includes a processor configured to receive the therapy target for the patient, receive a desired solute concentration for the patient, and apply the therapy target and the desired solute concentration as inputs to an optimization routine. The processor is also configured to execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate or a dialysis therapy dialysate flow rate. The processor is further configured to display the at least one dialysis therapy prescription for confirmation or selection by a clinician and transmit the selected or confirmed dialysis therapy prescription to a dialysis machine for a subsequent dialysis treatment for the patient.

Claims (79)

1 . A dialysis therapy system comprising:

a memory device storing a therapy target for a patient, the therapy target including at least one of (i) a target removal of ultrafiltration (“UF”), (ii) a target removal of beta 2-microglobulin (“β2-M”), (iii) a target removal of phosphate, or (iv) a target removal of urea; and

a processor communicatively coupled to the memory device and configured to

receive the therapy target for the patient,

receive a desired solute concentration for the patient,

apply the therapy target and the desired solute concentration as inputs to an optimization routine, the optimization routine being configured to use the therapy target and the desired solute concentration as the inputs for at least one kinetic modeling equation,

execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate (“Q B ”) or a dialysis therapy dialysate flow rate (“Q D ”),

display the at least one dialysis therapy prescription for confirmation or selection by a clinician, and

transmit the selected or confirmed dialysis therapy prescription to a dialysis machine to cause the dialysis machine to use the selected or confirmed dialysis therapy prescription for the patient,

wherein the at least one kinetic modeling equation includes:

K IC , which is the patient's inter-compartmental diffusion coefficient for a molecule or a solute,

K D , which is a known dialyzer clearance for a molecule or solute,

K M , which is the patient's phosphorus mobilization clearance,

K NR , which is the patient's residual kidney coefficient for a molecule or solute,

V is a distribution volume of phosphorus,

G, which is a generation rate for a solute or molecule produced by a patient's intake,

V P , which is a perfused or extracellular volume, and

V D , which is a solute distribution volume in a body, equal to V P +V NP for urea and beta2-microglubin.

2 . The system of claim 1 , wherein the at least one kinetic modeling equation further includes:

C P , which is an extracellular concentration of a solute,

C NP , which is an intracellular concentration of the solute

Φ NP , which is a ratio of intracellular compartment volume to a total distribution volume,

Φ P , which is the ratio of an extracellular compartment volume to the total distribution volume, and

α, which is an interdialytic fluid intake.

3 . The system of claim 1 , wherein the processor is further configured to:

execute a first iteration of the optimization routine;

perform a simulation using the determined at least one dialysis therapy prescription to determine a simulated therapy target for the patient;

compare the simulated therapy target to the therapy target; and

when at least one component of the simulated therapy target differs by a threshold from the therapy target, execute at least a second iteration of the optimization routine.

4 . The system of claim 1 , wherein the processor is further configured to:

receive a lifestyle preference related to the patient; and

filter the at least one dialysis therapy prescription for confirmation or selection based on the received lifestyle preference.

5 . The system of claim 4 , wherein the lifestyle preference includes at least one of a preferred daytime therapy duration, a preferred evening therapy duration, or a preferred number of dialysis therapies per week.

6 . The system of claim 1 , wherein the processor is further configured to:

receive a lifestyle preference related to the patient; and

recommend or select the at least one dialysis therapy prescription based on the received lifestyle preference.

7 . The system of claim 1 , wherein the processor is configured to transmit the selected or confirmed dialysis therapy prescription to the dialysis machine via a network connection to cause the dialysis machine to perform the subsequent dialysis treatment based on at least the corresponding dialysis therapy duration, the dialysis therapy frequency, and at least one of the dialysis therapy blood flow rate (“Q B ”), or the dialysis therapy dialysate flow rate (“Q D ”).

8 . The system of claim 1 , wherein the desired solute concentration includes at least one of a urea concentration, a beta 2-microglobulin (“β2-M”) concentration, or a phosphate concentration.

9 . The system of claim 1 , wherein the dialysis treatment includes at least one of a hemodialysis treatment, a hemofiltration treatment, a hemodiafiltration treatment, a peritoneal dialysis treatment, or a continuous renal replacement therapy (“CRRT”) treatment.

10 . A renal failure blood therapy system comprising:

a renal failure blood therapy machine configured to administer a renal failure blood treatment to a patient according to a therapy prescription; and

a computing device communicatively coupled to the renal failure blood therapy machine and configured to

receive a therapy target for the patient, the therapy target including at least one of (i) a target removal of ultrafiltration (“UF”), (ii) a target removal of beta 2-microglobulin (“β2-M”), (iii) a target removal of phosphate, or (iv) a target removal of urea,

receive a desired solute concentration for the patient,

apply the therapy target and the desired solute concentration as inputs to an optimization routine, the optimization routine being configured to use the therapy target and the desired solute concentration as the inputs for at least one kinetic modeling equation,

execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate (“Q B ”) or a dialysis therapy dialysate flow rate (“Q D ”),

display the at least one dialysis therapy prescription for confirmation or selection by a clinician, and

transmit the selected or confirmed dialysis therapy prescription to the renal failure blood therapy machine to cause the renal failure blood therapy machine to use the selected or confirmed dialysis therapy prescription for the patient,

wherein the at least one kinetic modeling equation includes:

K IC , which is the patient's inter-compartmental diffusion coefficient for a molecule or a solute,

K D , which is a known dialyzer clearance for a molecule or solute,

K M , which is the patient's phosphorus mobilization clearance,

K NR , which is the patient's residual kidney coefficient for a molecule or solute,

V is a distribution volume of phosphorus,

G, which is a generation rate for a solute or molecule produced by a patient's intake,

V P , which is a perfused or extracellular volume, and

V D , which is a solute distribution volume in a body, equal to V P +V NP for urea and beta2-microglubin.

11 . The system of claim 1 , wherein the dialysis treatment includes at least one of a hemodialysis treatment, a hemofiltration treatment, a hemodiafiltration treatment, a peritoneal dialysis treatment, or a continuous renal replacement therapy (“CRRT”) treatment.

12 . The system of claim 10 , wherein the computing device is further configured to:

receive a lifestyle preference related to the patient; and

recommend or select the at least one dialysis therapy prescription based on the received lifestyle preference.

13 . The system of claim 10 , wherein the computing device includes at least one of a handheld client device, a personal computer client device, or a server.

14 . The system of claim 10 , wherein the at least one kinetic modeling equation further includes:

C P , which is an extracellular concentration of a solute,

C NP , which is an intracellular concentration of the solute

Φ NP , which is a ratio of intracellular compartment volume to a total distribution volume,

Φ P , which is the ratio of an extracellular compartment volume to the total distribution volume, and

α, which is an interdialytic fluid intake.

15 . The system of claim 10 , wherein the computing device is further configured to:

execute a first iteration of the optimization routine;

perform a simulation using the determined at least one dialysis therapy prescription to determine a simulated therapy target for the patient;

compare the simulated therapy target to the therapy target; and

when at least one component of the simulated therapy target differs by a threshold from the therapy target, execute at least a second iteration of the optimization routine.

16 . The system of claim 10 , wherein the computing device is further configured to:

receive a lifestyle preference related to the patient; and

filter the at least one dialysis therapy prescription for confirmation or selection based on the received lifestyle preference.

17 . The system of claim 16 , wherein the lifestyle preference includes at least one of a preferred daytime therapy duration, a preferred evening therapy duration, or a preferred number of dialysis therapies per week.

18 . The system of claim 12 , wherein the computing device is configured to transmit the selected or confirmed dialysis therapy prescription to the renal failure blood therapy machine via a network connection to cause the renal failure blood therapy machine to perform the subsequent dialysis treatment based on at least the corresponding dialysis therapy duration, the dialysis therapy frequency, and at least one of the dialysis therapy blood flow rate (“Q B ”), or the dialysis therapy dialysate flow rate (“Q D ”).

19 . The system of claim 12 , wherein the desired solute concentration includes at least one of a urea concentration, a beta 2-microglobulin (“β2-M”) concentration, or a phosphate concentration.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER HEALTHCARE SA
To: VANTIVE HEALTH GMBH
Reel/Frame 074042/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER INTERNATIONAL INC.
To: VANTIVE US HEALTHCARE LLC
Reel/Frame 074047/0140 →
SECURITY INTEREST Recorded Jan 31, 2025
From: VANTIVE US HEALTHCARE LLC; GAMBRO RENAL PRODUCTS, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 070076/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2022
From: AKONUR, ALP; LEYPOLDT, JOHN KENNETH; LO, YING-CHENG; AGAR, BARIS UGUR
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 059467/0970 →